| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected but not Quantified |
|---|
| Creation Date | 2021-09-11 18:26:42 UTC |
|---|
| Update Date | 2021-09-26 23:13:51 UTC |
|---|
| HMDB ID | HMDB0257458 |
|---|
| Secondary Accession Numbers | None |
|---|
| Metabolite Identification |
|---|
| Common Name | Salicylamide glucuronide |
|---|
| Description | 3,4,5-trihydroxy-6-[2-(C-hydroxycarbonimidoyl)phenoxy]oxane-2-carboxylic acid belongs to the class of organic compounds known as phenolic glycosides. These are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans, and flavonoids. Among the sugar units found in natural glycosides are D-glucose, L-Fructose, and L rhamnose. Based on a literature review very few articles have been published on 3,4,5-trihydroxy-6-[2-(C-hydroxycarbonimidoyl)phenoxy]oxane-2-carboxylic acid. This compound has been identified in human blood as reported by (PMID: 31557052 ). Salicylamide glucuronide is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Salicylamide glucuronide is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
|---|
| Structure | NC(=O)C1=CC=CC=C1OC1OC(C(O)C(O)C1O)C(O)=O InChI=1S/C13H15NO8/c14-11(18)5-3-1-2-4-6(5)21-13-9(17)7(15)8(16)10(22-13)12(19)20/h1-4,7-10,13,15-17H,(H2,14,18)(H,19,20) |
|---|
| Synonyms | | Value | Source |
|---|
| 3,4,5-Trihydroxy-6-[2-(C-hydroxycarbonimidoyl)phenoxy]oxane-2-carboxylate | Generator |
|
|---|
| Chemical Formula | C13H15NO8 |
|---|
| Average Molecular Weight | 313.262 |
|---|
| Monoisotopic Molecular Weight | 313.079766447 |
|---|
| IUPAC Name | 6-(2-carbamoylphenoxy)-3,4,5-trihydroxyoxane-2-carboxylic acid |
|---|
| Traditional Name | 6-(2-carbamoylphenoxy)-3,4,5-trihydroxyoxane-2-carboxylic acid |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | NC(=O)C1=CC=CC=C1OC1OC(C(O)C(O)C1O)C(O)=O |
|---|
| InChI Identifier | InChI=1S/C13H15NO8/c14-11(18)5-3-1-2-4-6(5)21-13-9(17)7(15)8(16)10(22-13)12(19)20/h1-4,7-10,13,15-17H,(H2,14,18)(H,19,20) |
|---|
| InChI Key | AEMUKQHDNNVAES-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as phenolic glycosides. These are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans, and flavonoids. Among the sugar units found in natural glycosides are D-glucose, L-Fructose, and L rhamnose. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic oxygen compounds |
|---|
| Class | Organooxygen compounds |
|---|
| Sub Class | Carbohydrates and carbohydrate conjugates |
|---|
| Direct Parent | Phenolic glycosides |
|---|
| Alternative Parents | |
|---|
| Substituents | - Phenolic glycoside
- 1-o-glucuronide
- O-glucuronide
- Glucuronic acid or derivatives
- O-glycosyl compound
- Phenoxy compound
- Phenol ether
- Beta-hydroxy acid
- Monocyclic benzene moiety
- Hydroxy acid
- Monosaccharide
- Benzenoid
- Pyran
- Oxane
- Secondary alcohol
- Acetal
- Carboximidic acid
- Carboximidic acid derivative
- Carboxylic acid derivative
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Oxacycle
- Organoheterocyclic compound
- Polyol
- Organopnictogen compound
- Organic oxide
- Hydrocarbon derivative
- Carbonyl group
- Alcohol
- Organic nitrogen compound
- Organonitrogen compound
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 3.23 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.5679 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 7.46 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 796.7 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 254.4 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 63.2 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 177.2 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 76.4 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 272.4 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 287.9 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 770.8 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 603.2 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 158.6 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 898.6 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 202.1 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 216.4 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 555.2 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 418.6 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 347.1 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Salicylamide glucuronide,5TMS,isomer #1 | C[Si](C)(C)NC(=O)C1=CC=CC=C1OC1OC(C(=O)O[Si](C)(C)C)C(O[Si](C)(C)C)C(O[Si](C)(C)C)C1O[Si](C)(C)C | 2854.5 | Semi standard non polar | 33892256 | | Salicylamide glucuronide,5TMS,isomer #1 | C[Si](C)(C)NC(=O)C1=CC=CC=C1OC1OC(C(=O)O[Si](C)(C)C)C(O[Si](C)(C)C)C(O[Si](C)(C)C)C1O[Si](C)(C)C | 2722.1 | Standard non polar | 33892256 | | Salicylamide glucuronide,5TMS,isomer #1 | C[Si](C)(C)NC(=O)C1=CC=CC=C1OC1OC(C(=O)O[Si](C)(C)C)C(O[Si](C)(C)C)C(O[Si](C)(C)C)C1O[Si](C)(C)C | 3013.3 | Standard polar | 33892256 | | Salicylamide glucuronide,5TMS,isomer #2 | C[Si](C)(C)OC(=O)C1OC(OC2=CC=CC=C2C(=O)N([Si](C)(C)C)[Si](C)(C)C)C(O[Si](C)(C)C)C(O)C1O[Si](C)(C)C | 2887.1 | Semi standard non polar | 33892256 | | Salicylamide glucuronide,5TMS,isomer #2 | C[Si](C)(C)OC(=O)C1OC(OC2=CC=CC=C2C(=O)N([Si](C)(C)C)[Si](C)(C)C)C(O[Si](C)(C)C)C(O)C1O[Si](C)(C)C | 2806.9 | Standard non polar | 33892256 | | Salicylamide glucuronide,5TMS,isomer #2 | C[Si](C)(C)OC(=O)C1OC(OC2=CC=CC=C2C(=O)N([Si](C)(C)C)[Si](C)(C)C)C(O[Si](C)(C)C)C(O)C1O[Si](C)(C)C | 3225.8 | Standard polar | 33892256 | | Salicylamide glucuronide,5TMS,isomer #3 | C[Si](C)(C)OC(=O)C1OC(OC2=CC=CC=C2C(=O)N([Si](C)(C)C)[Si](C)(C)C)C(O)C(O[Si](C)(C)C)C1O[Si](C)(C)C | 2861.4 | Semi standard non polar | 33892256 | | Salicylamide glucuronide,5TMS,isomer #3 | C[Si](C)(C)OC(=O)C1OC(OC2=CC=CC=C2C(=O)N([Si](C)(C)C)[Si](C)(C)C)C(O)C(O[Si](C)(C)C)C1O[Si](C)(C)C | 2742.7 | Standard non polar | 33892256 | | Salicylamide glucuronide,5TMS,isomer #3 | C[Si](C)(C)OC(=O)C1OC(OC2=CC=CC=C2C(=O)N([Si](C)(C)C)[Si](C)(C)C)C(O)C(O[Si](C)(C)C)C1O[Si](C)(C)C | 3184.2 | Standard polar | 33892256 | | Salicylamide glucuronide,5TMS,isomer #4 | C[Si](C)(C)OC1C(OC2=CC=CC=C2C(=O)N([Si](C)(C)C)[Si](C)(C)C)OC(C(=O)O)C(O[Si](C)(C)C)C1O[Si](C)(C)C | 2872.8 | Semi standard non polar | 33892256 | | Salicylamide glucuronide,5TMS,isomer #4 | C[Si](C)(C)OC1C(OC2=CC=CC=C2C(=O)N([Si](C)(C)C)[Si](C)(C)C)OC(C(=O)O)C(O[Si](C)(C)C)C1O[Si](C)(C)C | 2716.1 | Standard non polar | 33892256 | | Salicylamide glucuronide,5TMS,isomer #4 | C[Si](C)(C)OC1C(OC2=CC=CC=C2C(=O)N([Si](C)(C)C)[Si](C)(C)C)OC(C(=O)O)C(O[Si](C)(C)C)C1O[Si](C)(C)C | 3153.7 | Standard polar | 33892256 | | Salicylamide glucuronide,5TMS,isomer #5 | C[Si](C)(C)OC(=O)C1OC(OC2=CC=CC=C2C(=O)N([Si](C)(C)C)[Si](C)(C)C)C(O[Si](C)(C)C)C(O[Si](C)(C)C)C1O | 2863.1 | Semi standard non polar | 33892256 | | Salicylamide glucuronide,5TMS,isomer #5 | C[Si](C)(C)OC(=O)C1OC(OC2=CC=CC=C2C(=O)N([Si](C)(C)C)[Si](C)(C)C)C(O[Si](C)(C)C)C(O[Si](C)(C)C)C1O | 2742.6 | Standard non polar | 33892256 | | Salicylamide glucuronide,5TMS,isomer #5 | C[Si](C)(C)OC(=O)C1OC(OC2=CC=CC=C2C(=O)N([Si](C)(C)C)[Si](C)(C)C)C(O[Si](C)(C)C)C(O[Si](C)(C)C)C1O | 3191.6 | Standard polar | 33892256 | | Salicylamide glucuronide,6TMS,isomer #1 | C[Si](C)(C)OC(=O)C1OC(OC2=CC=CC=C2C(=O)N([Si](C)(C)C)[Si](C)(C)C)C(O[Si](C)(C)C)C(O[Si](C)(C)C)C1O[Si](C)(C)C | 2903.7 | Semi standard non polar | 33892256 | | Salicylamide glucuronide,6TMS,isomer #1 | C[Si](C)(C)OC(=O)C1OC(OC2=CC=CC=C2C(=O)N([Si](C)(C)C)[Si](C)(C)C)C(O[Si](C)(C)C)C(O[Si](C)(C)C)C1O[Si](C)(C)C | 2729.4 | Standard non polar | 33892256 | | Salicylamide glucuronide,6TMS,isomer #1 | C[Si](C)(C)OC(=O)C1OC(OC2=CC=CC=C2C(=O)N([Si](C)(C)C)[Si](C)(C)C)C(O[Si](C)(C)C)C(O[Si](C)(C)C)C1O[Si](C)(C)C | 2948.5 | Standard polar | 33892256 | | Salicylamide glucuronide,5TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)C1=CC=CC=C1OC1OC(C(=O)O[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)C1O[Si](C)(C)C(C)(C)C | 3767.5 | Semi standard non polar | 33892256 | | Salicylamide glucuronide,5TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)C1=CC=CC=C1OC1OC(C(=O)O[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)C1O[Si](C)(C)C(C)(C)C | 3578.0 | Standard non polar | 33892256 | | Salicylamide glucuronide,5TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)C1=CC=CC=C1OC1OC(C(=O)O[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)C1O[Si](C)(C)C(C)(C)C | 3467.2 | Standard polar | 33892256 | | Salicylamide glucuronide,5TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)C1OC(OC2=CC=CC=C2C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)C(O)C1O[Si](C)(C)C(C)(C)C | 3823.5 | Semi standard non polar | 33892256 | | Salicylamide glucuronide,5TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)C1OC(OC2=CC=CC=C2C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)C(O)C1O[Si](C)(C)C(C)(C)C | 3692.9 | Standard non polar | 33892256 | | Salicylamide glucuronide,5TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)C1OC(OC2=CC=CC=C2C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)C(O)C1O[Si](C)(C)C(C)(C)C | 3573.2 | Standard polar | 33892256 | | Salicylamide glucuronide,5TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC(=O)C1OC(OC2=CC=CC=C2C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(O)C(O[Si](C)(C)C(C)(C)C)C1O[Si](C)(C)C(C)(C)C | 3785.5 | Semi standard non polar | 33892256 | | Salicylamide glucuronide,5TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC(=O)C1OC(OC2=CC=CC=C2C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(O)C(O[Si](C)(C)C(C)(C)C)C1O[Si](C)(C)C(C)(C)C | 3625.0 | Standard non polar | 33892256 | | Salicylamide glucuronide,5TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC(=O)C1OC(OC2=CC=CC=C2C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(O)C(O[Si](C)(C)C(C)(C)C)C1O[Si](C)(C)C(C)(C)C | 3541.6 | Standard polar | 33892256 | | Salicylamide glucuronide,5TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)OC1C(OC2=CC=CC=C2C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)OC(C(=O)O)C(O[Si](C)(C)C(C)(C)C)C1O[Si](C)(C)C(C)(C)C | 3819.2 | Semi standard non polar | 33892256 | | Salicylamide glucuronide,5TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)OC1C(OC2=CC=CC=C2C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)OC(C(=O)O)C(O[Si](C)(C)C(C)(C)C)C1O[Si](C)(C)C(C)(C)C | 3584.8 | Standard non polar | 33892256 | | Salicylamide glucuronide,5TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)OC1C(OC2=CC=CC=C2C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)OC(C(=O)O)C(O[Si](C)(C)C(C)(C)C)C1O[Si](C)(C)C(C)(C)C | 3527.5 | Standard polar | 33892256 | | Salicylamide glucuronide,5TBDMS,isomer #5 | CC(C)(C)[Si](C)(C)OC(=O)C1OC(OC2=CC=CC=C2C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)C1O | 3783.7 | Semi standard non polar | 33892256 | | Salicylamide glucuronide,5TBDMS,isomer #5 | CC(C)(C)[Si](C)(C)OC(=O)C1OC(OC2=CC=CC=C2C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)C1O | 3621.0 | Standard non polar | 33892256 | | Salicylamide glucuronide,5TBDMS,isomer #5 | CC(C)(C)[Si](C)(C)OC(=O)C1OC(OC2=CC=CC=C2C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)C1O | 3546.6 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (Non-derivatized) - 70eV, Positive | splash10-054k-9470000000-eadd100d212267335c11 | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_1_4) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_1_5) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_2_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_2_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_2_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_2_4) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_2_5) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_2_6) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_2_7) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_2_8) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_2_9) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_2_10) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_2_11) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_3_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_3_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_3_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_3_4) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_3_5) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_3_6) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylamide glucuronide GC-MS (TMS_3_7) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum |
NMR Spectra| Spectrum Type | Description | Deposition Date | Source | View |
|---|
| Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-10-27 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-10-27 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-10-27 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-10-27 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-10-27 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-10-27 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-10-27 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-10-27 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-10-27 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-10-27 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-10-27 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-10-27 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-10-27 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-10-27 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-10-27 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-10-27 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-10-27 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-10-27 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-10-27 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-10-27 | Wishart Lab | View Spectrum |
|
|---|